Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187000 | 0.87 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13570148 | 0.87 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL12635331 | 0.83 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL12635234 | 0.83 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL12635327 | 0.83 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13928223 | 0.80 | CTRB1 (0.44) | KMT2ATP53 | |
| SCHEMBL6795717 | 0.79 | KMT2A (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13688706 | 0.79 | CASP3 (0.57) | CASP3KMT2AEPHX2TLR2 | |
| SCHEMBL1784323 | 0.79 | CASP3 (0.57) | CASP3KMT2AEPHX2TLR2 | |
| SCHEMBL1784322 | 0.79 | CASP3 (0.57) | CASP3KMT2AEPHX2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | CASP3 10/4885KMT2A 4561/4885EPHX2 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.